CAR T cell killing requires the IFNγR pathway in solid but non-liquid tumors

  • Maude, SL et al. Tisagen lecleucel in children and young adults with B-cell lymphocytic leukemia. N. Engl. J. Med. 378439-448 (2018).

    CAS Article Google Scholar

  • Neelapu, SS et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large-cell B-cell lymphoma. N. Engl. J. Med. 3772531-2544 (2017).

    CAS Article Google Scholar

  • Locke, FL et al. Long-term safety and activity of the axicabtagene ciloleucel in refractory large cell B-cell lymphoma (ZUMA-1): single-arm, multicenter, phase 1-2 trials. Lancet Oncol. 2031-42 (2019).

    CAS Article Google Scholar

  • Schuster, SJ et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 3772545-2554 (2017).

    CAS Article Google Scholar

  • Wang, M. et al. KTE-X19 CAR T-cell therapy for recurrent or refractory mantle cell lymphoma. N. Engl. J. Med. 3821331-1342 (2020).

    CAS Article Google Scholar

  • Cohen, AD et al. B-cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 1292210-2221 (2019).

    Google Scholar article

  • Bagley, SJ, Desai, AS, Linette, GP, June, CH & O’Rourke, DM CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 201429-1438 (2018).

    CAS Article Google Scholar

  • Choi, BD, O’Rourke, DM & Maus, MV Construction of chimeric antigen receptor T cells for the treatment of glioblastoma. J. Target Ther. Cancer. 622-25 (2017).

    PubMed PubMed Central Google Scholar

  • Schmidts, A. & Maus, MV Make CAR T cells a solid option for solid tumors. In front of. Immunol. 92593 (2018).

    Google Scholar article

  • Doench, JG et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Night. Biotechnol. 34184-191 (2016).

    CAS Article Google Scholar

  • Sanson, KR et al. Optimized libraries for CRISPR-Cas9 genetic monitors with multiple modalities. Night. Common. 95416 (2018).

    ADS CAS Article Google Scholar

  • Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR / Cas9 knockout screens. By Biol. 15554 (2014).

    Google Scholar article

  • Bailey, SR et al. Blocking or deletion of IFNγ reduces macrophage activation without compromising CAR-T function in haematological malignancies. Blood Cancer Detect. 3136-153 (2022).

    PubMed Google Scholar

  • Schroder, K., Hertzog, PJ, Ravasi, T. & Hume, DA Interferon-γ: an overview of signals, mechanisms and functions. J. Leukocyte Biol. 75163-189 (2004).

    CAS Article Google Scholar

  • Walker, AJ et al. Tumor antigen and receptor densities regulate the efficacy of a chimeric antigen receptor that targets anaplastic lymphomkinase. Moth. Ther. 252189-2201 (2017).

    CAS Article Google Scholar

  • Majzner, RG et al. Adjustment of the antigen density requirement for CAR T cell activity. Cancer Discover. 10702-723 (2020).

    CAS Article Google Scholar

  • Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition of ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 193153-3164 (2013).

    CAS Article Google Scholar

  • Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells show an increased therapeutic index against tumors in mice. Cancer Res. 753596-3607 (2015).

    CAS Article Google Scholar

  • Brown, CE et al. Regression of glioblastoma after chimeric antigen receptor T cell therapy. N. Engl. J. Med. 3752561-2569 (2016).

    CAS Article Google Scholar

  • Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR / Cas9 improves tumor rejection. Nature 543113-117 (2017).

    ADS CAS Article Google Scholar

  • Stenger, D. et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR / Cas9-mediated TCR knockout CAR. Blood 1361407-1418 (2020).

    Google Scholar article

  • Mineo, M. et al. Tumor interferon signaling is regulated by an lncRNA INCR1 transcribed from PD-L1 place. Moth. Cell 781207-1223.e1208 (2020).

    CAS Article Google Scholar

  • Singh, N. et al. Decreased death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. Cancer Discover. 10552-567 (2020).

    CAS Article Google Scholar

  • Olli Dufva, JK et al. Integrated drug profiling and CRISPR screening identify significant pathways for CAR T cell cytotoxicity. Blood 135597-609 (2020).

    Google Scholar article

  • Davignon, D., Martz, E., Reynolds, T., Kürzinger, K. & Springer, TA Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen separated from Lyt-2,3 that participates in T lymphocyte-mediated drab. Proc. Natl Acad. Sci. USA 784535-4539 (1981).

    ADS CAS Article Google Scholar

  • Petit, A.-E. et al. A major secretory defect of tumor-infiltrating T lymphocytes due to galectin-inhibiting LFA-1-mediated synapse supplementation. Night. Common. 712242 (2016).

    ADS CAS Article Google Scholar

  • Bachmann, MF et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7549-557 (1997).

    CAS Article Google Scholar

  • Majzner, R. et al. CD58 aberrations limit lasting responses to CD19 CAR in patients with large B-cell lymphoma treated with axicabtagene ciloleucel, but can be overcome through new CAR techniques. Blood 13653-54 (2020).

    Google Scholar article

  • Frangieh, CJ et al. Multimodal pooled Perturb-CITE-seq monitors in patient models define mechanisms of cancer immunosuppression. Night. Genet. 53332-341 (2021).

    CAS Article Google Scholar

  • Davenport, AJ et al. Chimeric antigen receptor T cells produce non-classical and potent immune synapses that drive rapid cytotoxicity. Proc. Natl Acad. Sci. USA 115E2068 – E2076 (2018).

    CAS Article Google Scholar

  • Sade-Feldman, M. et al. Resistance to control point block therapy through inactivation of antigen presentation. Night. Common. 81136 (2017).

    Google Scholar ADS Article

  • Benmebarek, MR et al. Killing mechanisms for chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci. 201283 (2019).

    CAS Article Google Scholar

  • Manguso, RT et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547413-418 (2017).

    CAS Article Google Scholar

  • Patel, SJ et al. Identification of essential genes for cancer immunotherapy. Nature 548537-542 (2017).

    ADS CAS Article Google Scholar

  • Pan, D. et al. A major chromatin regulator determines the resistance of tumor cells to T cell-mediated killing. Science 359770-775 (2018).

    ADS CAS Article Google Scholar

  • Lawson, KA et al. Functional genomic landscape of cancer-inherent evasion of T cell killing. Nature 586120-126 (2020).

    ADS CAS Article Google Scholar

  • Wong, D. & Dorovini-Zis, K. Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain micro-endothelial cells by cytokines and lipopolysaccharide. J. Neuroimmunol. 3911-21 (1992).

    CAS Article Google Scholar

  • Song, M. et al. Low dose IFNγ induces tumor cell strain in tumor microenvironment of non-small cell lung cancer. Cancer Res. 793737-3748 (2019).

    CAS Article Google Scholar

  • Arenas, EJ et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeted HER2 through JAK2 down-modulation. Night. Common. 121237 (2021).

    ADS CAS Article Google Scholar

  • Dong, E. et al. IFN-γ overcomes PD-L1 / PD1 inhibition of CAR-T cell therapy by upregulating ICAM-1 on tumor cells. Signal transduction. Targ. Ther. 620 (2021).

    Google Scholar article

  • Lei, K. et al. Cancer cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. Night. Biomed. Meadow. 51411-1425 (2021).

    CAS Article Google Scholar

  • Basu, R. et al. Cytotoxic T cells use mechanical force to amplify target cell killing. Cell 165100-110 (2016).

    CAS Article Google Scholar

  • Johnson, LA et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Overs. With. 7275ra222 (2015).

    Google Scholar article

  • Brown, CE et al. Optimization of IL13Ra2-targeted chimeric antigen receptor T cells for improved antitumor efficacy against glioblastoma. Moth. Ther. 2631-44 (2018).

    CAS Article Google Scholar

  • Porter, DL, Levine, BL, Kalos, M., Bagg, A. & June, CH Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365725-733 (2011).

    CAS Article Google Scholar

  • Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 1063360-3365 (2009).

    ADS CAS Article Google Scholar

  • Carpenter, RO et al. B-cell maturation antigen is a promising target for adoptive T-cell treatment of multiple myeloma. Clin. Cancer Res. 192048-2060 (2013).

    CAS Article Google Scholar

  • An, Z. et al. EGFR collaborates with EGFRvIII to recruit macrophages in glioblastoma. Cancer Res. 786785-6794 (2018).

    CAS Article Google Scholar

  • Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Night. Protoc. 12828-863 (2017).

    CAS Article Google Scholar

  • Schindelin, J. et al. Fiji: an open source platform for biological image analysis. Night. Methods 9676-682 (2012).

    CAS Article Google Scholar

  • Ershov, D. et al. Bringing TrackMate into an era of machine learning and deep learning. Pre-print at BioRxiv https://doi.org/10.1101/2021.09.03.458852 (2021).

  • Leave a Comment